id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-305039-grsv06j7	Flego, Michela	Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases	2013-01-04		.txt	text/plain	10985	476	37	As for HIV, mAbs directed against spike viral proteins, as well as against host receptors, may act at an early stage of infection by preventing the binding of the virus on the cell surface. In some chronic viral infections, virus-specific immune cells may persist in a 'non-functional' state, because of an imbalance of immunoregulatory signals involving multiple inhibitory and activating receptors, triggered by soluble factors and/or cell surface ligands. Therapeutic approaches using specific mAbs to block host immunosuppressive molecules (antagonism) or to trigger activating receptors (agonism) may be a valid strategy to restore immune cell function and treat various chronic viral infections. In a proof-of-concept passive immunization trial with humans, it has been demonstrated that a cocktail of the three broadly neutralizing mAbs -2G12, 4E10 and 2F5was able to delay viral rebound in patients whose infections were fully suppressed by antiretroviral treatment before administration of the antibodies [76] .	./cache/cord-305039-grsv06j7.txt	./txt/cord-305039-grsv06j7.txt